Live
Roche MediaRoche and Nurix Therapeutics Announce Global Collaboration | PharmExec - Pharmaceutical ExecutiveEndpoints NewsIncyte CEO sees $2B Vega deal aiding a post-Jakafi futureClinical OMICsCortical On/Off Switch Provides Sleep Benefits to Awake MiceClinical OMICsGLP-1 Drugs Linked to Lower Rates of Substance Use DisordersEndpoints NewsCity Therapeutics gets $99M to gather data on three RNAi medicinesClinical OMICsProPure™ Endotoxin-Free Proteins for Reliable Cancer ResearchClinical OMICsTARGA Imager Enables High-Resolution Imaging of Neurodevelopmental ModelsBioPharma DiveRoche stakes $700M on Nurix’s protein-degrading drugClinical OMICsSignatera™ as a Pan-Cancer Decision-Making Tool to Illuminate the Care PathwayEndpoints NewsGoHealth files for bankruptcy, as Medicare Advantage insurers pull backAgilentHow Investors May Respond To Agilent Technologies (A) Expanding AI-Enabled Lab Solutions And Oncology Diagnostics - simplywall.stAgilentHow Investors May Respond To Agilent Technologies (A) Expanding AI-Enabled Lab Solutions And Oncology Diagnostics - simplywall.st
PLoS Biology 22 avr. 2026

Structure of the human P2X3 receptor reveals the basis for subtype-selective inhibition by sivopixant

Structure of the human P2X3 receptor reveals the basis for subtype-selective inhibition by sivopixant

Original
Contenu indisponible. Consultez la source originale.